Sponsored Videos

David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials.

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research organization (CRO) partners to support clinical trials that are patient-first and accessible.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, touches on the usability of clinical technology.

Liz Rogers, VP and Head of Global Site and Study Operations at Pfizer, discusses Pfizer's partnership with Parexel and transition to a functional service provider (FSP) model.

Jenny Denney, EVP, Head of FSP Clinical and Biometrics at Parexel, discusses current transformations in the industry in addition to how Parexel, as the landscape shifts, supports clients with proper models and infrastructure from a functional service provider (FSP) perspective.

Jon Ernst (Vice President, In-Home Solutions, Decentralized Clinical Trials) discusses today's clinical trial landscape.

Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.

In this video, Dr Loren Blake (Study Director, FSP Solutions) and Jack Bradley (Executive Director) from LabConnect share their keen insights on the challenges that sponsors currently face in clinical trials, as well as ways to overcome them to accelerate outcomes.

Cat Hall, Vice President of Data and Quality, endpoint Clinical, provides insight on managing Interactive Response Technology audit data to avoid delays, ensure regulatory compliance and maintain data integrity for trial success.

Sonja Wustrack, OM1, highlights a new clinical study automation platform to support critical data collection and real-world evidence.

Esther Howard, Oncology Advisor at THREAD, will be shedding light on how DCT design brings clinical research as a care option to cancer patients. In 2021, over 608,000 Americans alone passed away from cancer- equating to 1,600 deaths a day. Because clinical trials become the only treatment option for cancer patients after they have exhausted all standard of care options, we desperately need solutions to bring real access to clinical trials as a care option to more cancer patients. Esther will focus on some of the challenges that patients face, and how elements of a DCT design can not only save the lives of more patients but can also be a key driver in improving diversity in enrollment.

Watch our roundtable participants discuss the Next Best in Patient Centricity, with topics including the meaning of patient centricity; how to increase patient engagement in clinical trials; data and technology; and the site perspective.

Nagaraja Srivatsan, SVP & Chief Digital Officer at IQVIA, breaks down the most recent challenges in the decentralized trial space: patient burden, the ecosystem between the patient and information, and the global regulatory landscape.

Almac provides an overview of their clinical technologies branch, their IRT offerings, and the current changes to the clinical development industry.

YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.

R&D growth from biotech and emerging biopharma companies is strong. With that comes a transformation of the end-to-end services needed to meet the strategic, clinical, and operational needs of these smaller companies. Join this podcast to learn about clinical development and outsourcing trends that emerged in 2021 and a discussion of what to expect in 2022.

This video series discusses the impact of implementing risk-based quality management (RBQM) and decentralized clinical trials (DCTs) from the clinical operations point of view.

In a recent virtual roundtable discussion, industry experts Jim Streeter, Alison Holland, Hassan Kadhim, Craig Lipset, Josh Rose, and Craig Serra shared their insight on the challenges faced in implementing decentralized trials and how to address them. Along with the roundtable are video discussions covering the cost and feasibility of a toolkit approach to decentralized trials, the significance of minimizing burden to patients and sites, and the reality of regulatory hurdles.

ACT’s Lisa Henderson interviews John Potthoff, PhD, CEO of Elligo Health Research, about decentralizing and restarting clinical trials amid the COVID-19 pandemic.